Merck price forecast: sideways ahead? Rally stalls near resistance at $115.75

Traders Union
All News
Financial News
Merck KGaA rises 1.95% today

Highlights

Merck KGaA (MRK) trades at $115.15, above its MA-20 ($114.43) and MA-50 ($111.28) but below MA-200 ($120.69), indicating short-term bullishness amid persistent long-term downward pressure.
Surging European demand for its RSV vaccine and positive Phase 3 Ogsiveo® data enhance Merck's healthcare revenue prospects and market confidence.
Despite strong bullish momentum indicators, MRK faces less than 20% probability of price increase next week, with baseline expectation for sideways trading between $113.45 and $115.75.

RSV vaccine demand and trial results bolster healthcare outlook

Merck reported a surge in demand for its RSV vaccine in Europe, highlighting strong revenue prospects for its healthcare business. The company also issued a regulatory announcement regarding major shareholder holdings and voting rights, updating investors on shifts in the corporate ownership structure. In addition, Merck released positive long-term Phase 3 trial data for Ogsiveo®, further supporting market confidence.

Bullish momentum and mixed signals as oscillators diverge

Momentum indicators show mixed signals on the daily timeframe. MACD is strongly bullish, and ADX confirms the presence of a robust upward trend, while RSI sits in neutral-bullish territory and Stochastic RSI points to oversold conditions. BBP remains negative, suggesting sellers still influence near-term moves. Awesome Oscillator aligns with the upward trend. After a mild gap down at the open ($112.95 to $112.50), MRK advanced $2.20 or 1.95%, currently sitting near today’s range high ($112.50–$115.75) with moderate intraday volatility. This move demonstrates clear strength toward session highs, though the presence of both bullish momentum and oversold signals indicates some divergence among oscillators.

Sideways bias amid low upside odds and defined price range

The forecasted range for the next five trading days is $113.45–$115.75. The probability of a price increase is very low (less than 20%), making further declines more likely. The baseline scenario calls for the price to remain sideways within this corridor. In a bullish scenario, MRK could retest resistance near $115.75 and push higher. If bearish momentum prevails, a break below $113.45 opens the path toward lower support levels.

Anton Kharitonov, expert at Traders Union, sees Merck KGaA’s near-term setup as technically constructive but fundamentally limited, with short-term bullish signals overshadowed by a persistent long-term downtrend and a low probability of breakout. He notes that while positive healthcare news and robust demand offer some support, mixed momentum signals and dominant seller influence restrict clear upside potential. Kharitonov remains cautious given the likelihood of further sideways or downward action within the $113.45–$115.75 range. "Base case remains range-bound — until the price convincingly reclaims the $120.69 level, I stay defensive on MRK."

Last time we reported that Merck began construction on a $3 billion pharmaceutical manufacturing facility in Elkton, Virginia, as part of a wider US expansion effort. Previously it was noted that the company surpassed earnings expectations, supporting its financial stability amid market fluctuations, as detailed in supporting its financial stability amid market fluctuations.

Source of Data: MRK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.